Key Takeaways
- First call as a public company, strong FY25: Revenue grew 28% YoY to ₹162.92 crores and PAT jumped 55.63% YoY to ₹9.82 crores, aided by IPO interest income.
- Repeat customer ratio is the core metric: The ratio improved from ~22% to 25% QoQ through personalized health-goal flows and proactive reengagement, and management expects further QoQ gains.
- A new employee model is compressing costs: Employees with 2+ years tenure now work fewer hours for lower payout relative to CTC, so total employee benefit expenses fell even as headcount rose.
- The ₹500 crore aspiration rests on geography and AI: The three-year target leans on pin code expansion from 11,600 to 19,000, entry into new states, and an AI-powered support layer now in test phase.
- What to watch next quarter: Whether the repeat ratio keeps climbing, the North brand ambassador announcement lands, and any early revenue signal from the AI test phase.
The Repeat Engine
- Repeat ratio moved from ~22% to 25% QoQ: The company now runs personalized journeys, health-goal-based marketing flows (sexual wellness, addiction recovery, diabetes lifestyles), and proactive call reengagement every 30-60 days. These processes were previously absent as the company scaled, and are now regularized.
- PlantoMed brings a 60% repeat blueprint: The small acquisition was done for knowledge transfer, not revenue, because PlantoMed has a niche in diabetes and a repeat ratio of 60%.
- Lower-priced variants aim to capture lost market: A 15-day cycle product (vs the current 30-60 day) is planned to complement existing revenue without cannibalizing it.
- Management is hopeful the ratio will keep rising QoQ: The expectation is that the newly inculcated processes will compound.
Cost Structure & Margin Levers
- Employee costs fell despite headcount growth: A new model introduced in H2 gives employees with 2+ years tenure fewer hours/days and lower payout relative to CTC, so total employee benefit expenses declined.
- Fixed cost leverage is a stated margin driver: Salary and infrastructure sit at 26%-28% of revenue with a large fixed component; management says current capacity can support ₹210 crores turnover, which would pull ~3% of margin from that base.
- Advertisement spend is treated as investment, not expense: The 42% absolute increase in other expenses was driven by ad costs at ~3% of revenue; brand ambassador costs will be capitalized and reflect over time. Management expects ad spend today to show growth in H1 but far more in H2 and future years.
- No price increases on current products: Average ticket size has risen over 24 months by testing new products at higher price points, not by raising existing prices.
Manprit Singh Chadha: "We consider advertisement as an investment and not as a putting in money and then looking for it."
Operational Resilience & Asset-Light Model
- Two disruptions hit the quarter: Indo-Pak border tensions caused brief delivery disruptions as multiple courier partners halted services in key northern states, and a fire incident at one regional center temporarily impacted operations (no casualties, operations resumed quickly).
- The model is manufacturing-light: The company uses six third-party manufacturing partners, two of which manufacture exclusively for Sat Kartar; the other four have approval to manufacture for others but Sat Kartar holds a first right to stop if infringement occurs. Quality is managed through pre-production facility audits and post-production sample batch checks.
- Ayush Ministry provides regulatory cover: The Department of Ayush vets formulations, gives suggestions, and periodically audits manufacturing facilities for process compliance. The company also holds approvals from the National Research Development Corporation and the Central Council for Research in Ayurvedic Sciences.
- Negative working capital cycle: The company takes favorable payment cycles from suppliers and manufacturers while receiving payment upfront or within 4-5 days from customers.
Growth Geography & Channels
- Pin code expansion is the backbone: The company is on track to scale reach from 11,600 to over 19,000 pin codes in the next 12 to 18 months.
- New states are the next layer: Current presence covers Tamil Nadu, Karnataka, Andhra Pradesh, UP, Bihar, and Rajasthan; Gujarat, Maharashtra, the North East, and Jammu and Kashmir are identified as incremental revenue pools.
- Brand ambassadors are being deployed regionally: A brand ambassador has been taken in the South, and a North brand ambassador announcement is expected in the next 15 days.
- No export strategy for at least six months: Management may consider exports only at the end of FY26.
Product & Category Expansion
- Spiritual wellness is the newest category: The company has taken a conscious internal decision and approval to venture into spiritual products targeting mental well-being, sleep, and depression, leveraging the existing customer base. A few SKUs are expected by the next call.
- No new disease categories planned: The company will stay within its 16 remedies, developing the balance 8 and adding sub-SKUs under existing diseases rather than expanding into new therapeutic areas.
- AI-powered support is in test phase: A test phase is ready where AI talks to customers at the same quality as human support; the goal is to scale fast and handle odd-hour customer interactions.
Manprit Singh Chadha: "what began as a simple vision to make high-quality Ayurveda accessible across India has evolved into a data-driven wellness platform that sits at the intersection of tradition, technology, and scale."
Competitive Positioning
- Differentiation is human-to-human language, not product exclusivity: When pressed by an analyst who noted the product profile is not exclusive (diabetes and other conditions are catered to by others), management clarified the moat is language-centric interaction, not the formulations themselves.
- Management sees no direct competitor: The company declined to name competitors, stating it cannot find any direct competitor in its sphere.
Manprit Singh Chadha: "It's not because of my exclusive product; it's because of my exclusive human-to-human language-centric interaction."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue aspiration | Reach ₹500 crores top line | Three years |
| First revenue milestone | Touch ₹250 crores within the three major product segments | Unspecified (stepping stone to ₹500 crores) |
| Pin code expansion | Scale from 11,600 to over 19,000 pin codes | Next 12 to 18 months |
| PAT margin | At least 9% to 10% (FY26 internal benchmark) | FY26 |
| EBITDA margin | 15% to 20% | Unspecified |
| YoY revenue growth | 40%-50%, with ~7% QoQ cumulative growth | Ongoing |
| North brand ambassador | Announcement expected | Next 15 days |
| Spiritual offerings | A few SKUs added, update provided | By next earnings call |
| Monthly revenue updates | Provide monthly revenue disclosures | Starting now |
| Export strategy | No exports | At least next six months; reconsider at end of FY26 |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue | ₹48 cr (Q4 FY25), FY25 total ₹162.92 cr, +28% YoY |
| PAT | ₹9.82 cr (FY25), +55.63% YoY |
| PAT margin | 6% (FY25), targeting 9–10% in FY26 |
| Revenue growth guidance | 40–50% (FY26), implying ₹230–240 cr |
| PAT margin guidance | 9–10% (FY26 internal benchmark) |
| Advertisement cost | 40–42% of revenue |
| Repeat customer ratio | 25%, up from ~22% earlier |
| Consumer database | Over 3 crore consumers |
| Multilingual customer advisors | 800-plus |
| Pin code reach | Over 11,600, scaling to 19,000 in 12–18 months |
| Revenue concentration | 4 of 16 remedies contribute 80% of revenue |
| Salary and infrastructure cost | 26–28% of revenue, capacity supports turnover up to ₹210 cr |
| Q4 FY25 PAT margin | ~7% (per an analyst's math) |